コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 primarily cardiovascular and kidney disease risk-reducing agents with a side effect of glucose-lower
2 aling is a critical mechanism underlying the risk-reducing and therapeutic effects of antiestrogens.
3 isk of breast cancer and show that potential risk reducing anti-progesterone drugs can reverse this.
4 others, bisphosphonates may be an effective risk-reducing approach with the potential added benefits
5 nd that targeting low or high trophic levels risks reducing basal biomass or triggering trophic casca
8 t and sedentary lifestyle; limited access to risk-reducing behaviors such as chemoprevention, screeni
18 Tamoxifen and Raloxifene, which compares the risk-reducing efficacy as well as toxicity of these two
19 category with the strongest association) for risk-reducing foods or risk-increasing foods, respective
22 (HR = 0.61, 95% CI = 0.60, 0.63) or diabetes risk-reducing (HR = 0.70, 95% CI = 0.69, 0.72) diet had
23 SPSTF policy updates may improve adoption of risk-reducing interventions and shorten the time to diag
25 sting experience and in the effectiveness of risk-reducing interventions compound access and knowledg
26 ment interactions will inform more effective risk-reducing interventions for this vulnerable populati
27 k factors for melanoma and comments on which risk-reducing interventions pediatricians should institu
30 ortant implications for treatment decisions, risk-reducing interventions, cancer screening, and germl
34 umor features and treatments associated with risk-reducing interventions; for example, in most BRCA2
36 elina Jolie shared the news of her bilateral risk-reducing mastectomy (BRRM), on the basis of her BRC
38 ngo-oophorectomy (RRSO) and, where relevant, risk-reducing mastectomy (RRM) compared with nonsurgical
41 or without mammography, chemoprevention, or risk-reducing mastectomy and salpingo-oophorectomy, to r
42 bilateral salpingo-oophorectomy (RRBSO) and risk-reducing mastectomy are widely used for BRCA1 and B
43 cancers were diagnosed in the 247 women with risk-reducing mastectomy compared with 98 women of 1372
44 Among high-risk women and mutation carriers, risk-reducing mastectomy decreased breast cancer by 85%
45 ve shown that the number of women undergoing risk-reducing mastectomy has increased rapidly in the US
46 a contralateral breast cancer, contralateral risk-reducing mastectomy is often, but not universally,
48 ever, many patients undergoing contralateral risk-reducing mastectomy might not be categorised as hig
49 ional variant group, the potential impact of risk-reducing mastectomy on female cancer incidence, and
50 lso consider surgical interventions, such as risk-reducing mastectomy or risk-reducing salpingo-oopho
51 North America to assess the relationship of risk-reducing mastectomy or salpingo-oophorectomy with c
52 mmography screening, medical prevention, and risk-reducing mastectomy to reduce their breast cancer r
53 n with BRCA1 and BRCA2 mutations, the use of risk-reducing mastectomy was associated with a lower ris
55 on making in prioritization of research into risk-reducing measures, and inform case management in cl
59 sider integrating shared decision making for risk-reducing medication and screening on the basis of i
60 evaluate the lifetime benefits and harms of risk-reducing medication in women with a >= 3% 5-year ri
61 ngs suggest a need to re-evaluate the use of risk-reducing medication to avoid invasive breast cancer
66 The USPSTF found convincing evidence that risk-reducing medications (tamoxifen, raloxifene, or aro
68 ods to identify women who could benefit from risk-reducing medications for breast cancer, as well as
69 the effectiveness of intensive screening or risk-reducing medications in mutation carriers, although
70 ffects, clinicians should offer to prescribe risk-reducing medications, such as tamoxifen or raloxife
71 ecommends that clinicians offer to prescribe risk-reducing medications, such as tamoxifen, raloxifene
72 USPSTF recommends against the routine use of risk-reducing medications, such as tamoxifen, raloxifene
74 of childhood ALL and encourage the notion of risk-reducing microbiome-targeted intervention in the fu
77 group had a more favorable consideration of risk-reducing oophorectomy, from 7 women (14%) who refus
78 nd testing increased surveillance and led to risk-reducing operations, which resulted in diagnosis of
80 vides a framework for proactively evaluating risk, reducing potential adverse impacts of FPV to birds
81 ation of the potential benefit and risk of a risk-reducing procedure in a potentially otherwise healt
82 re cancer surveillance (eg, colonoscopy) and risk-reducing procedures (eg, bilateral mastectomy) with
83 ough a small rise in the number of bilateral risk-reducing procedures has been noted in high-risk gen
84 fallopian tube carcinomas identified through risk-reducing prophylactic oophorectomy from three women
85 clearly associated with poor compliance with risk-reducing recommendations, with abnormalities in aut
86 ov model evaluated the cost-effectiveness of risk-reducing salpingo-oophorectomy (RRSO) and, where re
91 l 2-stage alternative prevention strategy to risk-reducing salpingo-oophorectomy (RRSO) that avoids d
94 cancer risks, as well as risk reduction from risk-reducing salpingo-oophorectomy (RRSO), by CJM and s
95 genes, surgical risk reduction, particularly risk-reducing salpingo-oophorectomy (RRSO), has become a
96 on between risk-reducing mastectomy (RRM) or risk-reducing salpingo-oophorectomy (RRSO), or both proc
100 was diagnosed in 3 of the 98 women who chose risk-reducing salpingo-oophorectomy and peritoneal cance
102 to 100% compared with women without surgery; risk-reducing salpingo-oophorectomy decreased breast can
104 aperitoneal cancer in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy is highly likely the
109 sociated with a lower risk of breast cancer; risk-reducing salpingo-oophorectomy was associated with
110 We prospectively compared the effect of risk-reducing salpingo-oophorectomy with that of surveil
112 Compared with women who did not undergo risk-reducing salpingo-oophorectomy, undergoing salpingo
113 Compared with women who did not undergo risk-reducing salpingo-oophorectomy, women who underwent
117 Hence, colicin expressers may be engaged in risk-reducing strategies-or bet-hedging-as they balance
121 omy with delayed oophorectomy may be a novel risk-reducing strategy with benefits of delaying menopau
123 cades of surveillance of multiple organs and risk-reducing surgeries for GPV-carriers should be justi
124 Little evidence exists on the effect of risk-reducing surgeries in young BRCA carriers with a pr
126 rate for germline genetic testing and reflex risk-reducing surgery among patients with an affected fi
128 arriers may be offered interventions such as risk-reducing surgery and intensive surveillance over de
138 ll-being and led to a more favorable view on risk-reducing surgical procedures for at least 6 months
139 mes included sleep quality, attitudes toward risk-reducing surgical procedures, and psychosocial vari
141 tion is the primary driver of this increased risk, reducing the return period by approximately 5 time
142 centralizing decision-making authority, and risks reducing the diversity of methods and contributors
143 gements about an idea's value as a signal of risk, reducing their willingness to invest in the idea.
144 study evaluated clinical outcomes or use of risk-reducing therapies after screening versus no screen
145 to personalized estimation of benefits from risk-reducing therapies in primary prevention may help t
146 xamined the short- and long-term outcomes of risk-reducing total gastrectomy (RRTG) and its lesser-kn
147 history, genotype, and pathologic data from risk-reducing total gastrectomy and surveillance endosco
148 (93.8% [15 of 16 variants]) who elected for risk-reducing total gastrectomy owing to their underlyin